ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2026
Wnt/β-catenin signaling dysregulation in Alzheimer's disease and therapeutic opportunities.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by neuronal and neurovascular dysfunction. Wnt/β-catenin signaling is a highly conserved pathway that plays essential roles in central nervous system development and homeostasis, including regulation of neurogenesis, synaptic plasticity, neuronal survival, cerebrovascular development, and blood-brain barrier (BBB) maintenance. Growing evidence increasingly implicates disruption of Wnt/β-catenin signaling in multiple neuronal and neurovascular processes relevant to AD. This review summarizes current knowledge of the Wnt/β-catenin pathway and examines evidence linking its dysregulation to AD from human studies, omics datasets, experimental models, and patient-derived cellular systems. It focuses on endothelial Wnt/β-catenin dysfunction as a potential early contributor to BBB breakdown, rather than on neuronal Wnt signaling. We also emphasize its role in BBB development and maintenance, neurovascular dysfunction, and emerging evidence that endothelial Wnt/β-catenin impairment may contribute to BBB dysfunction in AD. Additionally, we discuss cell-type-specific effects of Wnt signaling and therapeutic strategies targeting glycogen synthase kinase (GSK-3β), extracellular Wnt antagonists, and BBB integrity. Although challenges remain regarding cell-type specificity, disease-stage dependence, safety, biomarker development, and the efficacy of preclinical-to-clinical translation for targeting the Wnt/β-catenin pathway, modulating Wnt/β-catenin signaling represents a potential therapeutic approach to preserve neuronal and neurovascular function in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.